Evotec AG is a drug discovery alliance and development partnership company focused on progressing product approaches with pharmaceutical and biotechnology companies.The company's headquarters are located in Hamburg, Germany. It operates worldwide providing integrated drug discovery solutions, covering all activities from target-to-clinic.Evotec employs over 500 scientists and works in key therapeutic areas including CNSAstraZeneca, Roche and UCB. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development.In fiscal year 2013, Evotec generated revenues of €85.94 m. At the end of September 2014, Evotec had 718 employees.Since 28 October 2009 the company is listed in the TecDAX index. Wikipedia.
News Article | May 3, 2017
HAMBURG, Germany--(BUSINESS WIRE)--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) will report its financial results for the first quarter of 2017 on Wednesday, 10 May 2017. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for the fiscal year 2017. The conference call will be held in English. A simultaneous slide presentation for participants dialling in via phone is available at www.audio-webcast.com, password: evotec0517. To join the audio webcast and to access the presentation slides you will find a link on our home page www.evotec.com shortly before the event. A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialling +49 69 22 22 33 985 (Germany) or +44 20 3426 2807 (UK) and in the USA by dialling +1 866 535 8030. The access code is 654573#. The on-demand version of the webcast will be available on our website: https://www.evotec.com/article/en/Investors/Finance/Financial-Reports-2015-2017/188/6/26. Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and with Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG. Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2013-ITN | Award Amount: 3.51M | Year: 2013
Brain disorders comprise a major burden for the society. Recent analyses of the neuropsychiatric disease-related gene polymorphisms as well as genomics and proteomics have identified the components of the extracellular matrix (ECM) and the cell adhesion molecules (CAMs) in the brain as pivotal for those diseases. The ECM/CAMs span the synaptic cleft and regulate the synaptic dynamics. Furthermore, recent studies have shown that proteolytic activity may release from the ECM/CAMs cryptic ligand(s) that activate cell surface receptors and initiate intracellular signalling cascade(s). Thus, ECM and its enzymatic modifications have emerged as a highly topical research area, also because their extracellular localization makes the development of enzymatic inhibitors more feasible. This proposal brings together a group of well-established academic and industrial partners sharing interest in the ECM and its proteolysis. In the proposal there is clearly an overlapping interest in specific brain conditions and structures to be investigated, making the consortium ideally suited to provide a comprehensive picture for the role of ECM proteolysis in brain function and dysfunctions. While the academic partners focus on specific research questions, the industrial members are to provide the entire consortium with high-throughput techniques and powerful research tools. This combination of conceptual scientific vision, tools and approaches should be of great benefit for the young researchers to be trained. The trainees will be exposed to courses, workshops, joint research meetings and inter-laboratory visits. The focus of the training program is on expanding knowledge and on developing new treatments to anxiety disorders, schizophrenia, mental retardation and Alzheimers. A unifying neurobiological concept in the consorted effort to tackle these conditions is the involvement of abnormal synaptic plasticity.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: EINFRA-5-2015 | Award Amount: 4.94M | Year: 2016
This Centre of Excellence will advance the role of computationally based modelling and simulation within biomedicine. Three related user communities lie at the heart of the CoE: academic, industrial and clinical researchers who all wish to build, develop and extend such capabilities in line with the increasing power of high performance computers. Three distinct exemplar research areas will be pursued: cardiovascular, molecularly-based and neuro-musculoskeletal medicine. Predictive computational biomedicine involves applications that are comprised of multiple components, arranged as far as possible into automated workflows in which data is taken, from an individual patient, processed, and combined into a model which produces predicted health outcomes. Many of the models are multiscale, requiring the coupling of two or more high performance codes. Computational biomedicine holds out the prospect of predicting the effect of personalised medical treatments and interventions ahead of carrying them out, with all the ensuing benefits. Indeed, in some cases, it is already doing so today. The CoE presents a powerful consortium of partners and has an outward facing nature and will actively train, disseminate and engage with these user communities across Europe and beyond. Because this field is new and growing rapidly, it offers numerous innovative opportunities. There are three SMEs and three enterprises within the project, as well as eight associate partners drawn from across the biomedical sector, who are fully aware of the vast potential of HPC in this domain. We shall work with them to advance the exploitation of HPC and will engage closely with medical professionals through our partner hospitals in order to establish modeling and simulation as an integral part of clinical decision making. Our CoE is thus user-driven, integrated, multidisciplinary, and distributed; presenting a vision that is in line with the Work Programme.
Evotec | Date: 2015-09-30
The present invention relates to the preparation of compounds of formula (I)^(1), R^(2), R^(2a), R^(3), X^(1) to X^(3) have the meaning as indicated in the description and claims and to intermediate compounds used to prepare compounds of formula (I).
Evotec | Date: 2014-04-03
The use of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl-4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt for treating various types of insomnia.
Evotec | Date: 2013-09-26
The present invention relates to formulations with protein growth factors, particularly neurturin as active ingredients and low molecular weight polyanionic excipients having increased bioavailability.
Evotec | Date: 2014-05-27
The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.
Evotec | Date: 2015-04-08
The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
Evotec | Date: 2013-11-07
The invention relates to compounds of formula (I) wherein R^(1), R^(1a), R^(1b), R^(2), R^(3 )and X, X^(1), X^(2), X^(3 )have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
Evotec | Date: 2013-02-22
The present invention discloses the protein pleitrophin secreted by the developing pancreas, and polynucleotides, which identify and encode this protein. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome.